What is the 13F Pro Quality Score for BTMD?

13F Pro ranks biote Corp. (BTMD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BTMD's current score at https://13fpro.ai/company/BTMD (free sign-up required for the full ranking).

Which hedge funds own the most BTMD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BTMD include 325 CAPITAL, Bandera Partners, VANGUARD CAPITAL MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/BTMD as soon as new 13F filings post.

Where does 13F Pro source BTMD data?

All biote Corp. fundamentals and ownership data come directly from SEC EDGAR. biote Corp. files with the SEC under CIK 1819253. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BTMD in?

biote Corp. (BTMD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BTMD research updated on 13F Pro?

BTMD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

biote Corp.(BTMD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1819253 BTMD stock profile & AI dashboard →

13F Pro Quality Score

39.6/100

Rank #2,141 of 2,962 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

19.0/100

Profitability

31.0/100

Balance Sheet

72.6/100

Earnings Quality

92.8/100

Free Cash Flow

57.4/100

Institutional Flow

3.5/100

Revenue Scale

22.7/100

Dilution Risk

25.9/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why BTMD Scores 40/100

exact factor attribution · 2026-09-11

BTMD's composite is driven by earnings quality and capital efficiency, held back by revenue growth and scale. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Earnings quality

+4.3 pts

93th pct

Capital efficiency

+2.3 pts

73th pct

Free cash flow

+1.1 pts

57th pct

Shareholder dilution

-1.2 pts

26th pct

Earnings growth

-1.4 pts

22th pct

Institutional flow

-2.3 pts

4th pct

Profitability

-2.9 pts

31th pct

Scale

-4.1 pts

23th pct

Revenue growth

-6.2 pts

19th pct

Latest change (2026-08-07): 57 → 43 · ↓ Profit margin 82→34; ↓ Capital efficiency 98→73; despite ↑ Earnings growth 30→58

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in BTMD

Events flagged as statistical outliers against BTMD's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-07
BTMD quality score dropped 14 points (57→43) on a new filing
View source filing →

BTMD Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for biote Corp. (BTMD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BTMD at 39.6/100 on a 32-signal composite quality model, placing it at rank #2,141 of 2,962 stocks — the bottom half of the AI-ranked universe. BTMD scores in the top quartile across earnings quality (92.8). Areas of concern include institutional flow (3.5) and revenue growth (19.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), biote Corp. reports quarterly revenue of $44.2M, net income of $-6.6M, free cash flow of $-3.7M. Top institutional holders of BTMD by reported 13-F value include 325 CAPITAL, Bandera Partners, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BTMD trades on the Nasdaq exchange and files with the SEC under CIK 1819253. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BTMD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for biote Corp. directly from SEC EDGAR. biote Corp.'s 13F Pro composite quality score has ranged between 30 and 63 since 2023, currently 39.6 — an improving long-term trajectory across 60 quarterly and live scoring snapshots.

✦

Fun facts about biote Corp.

Quirks, history, and lore behind BTMD — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · small-cap · listed on Nasdaq · headquartered in Texas.
2
The Numbers
The company has trained a network of thousands of certified physician practices across the U.S., making its revenue model lean heavily on licensing and training fees rather than direct patient care.
3
The History
Founded in the 2010s, it went public via a SPAC merger — perfectly on-trend for its era — and built its business around a medical niche that baby boomers care about a lot.
4
The Secret
Its entire platform is built around hormone optimization therapy — specifically pellet-based bioidentical hormone replacement administered by trained clinicians.
5
The Lore
The company essentially franchises a clinical protocol: it certifies doctors, supplies the pellets, and handles the back-office — turning hormone therapy into a repeatable, scalable business.
6
The Giveaway
Its name is a mashup of "bio" and a suffix that sounds like a treatment — a testosterone and estrogen pellet therapy company that has quietly built one of the largest hormone optimization networks in America.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q2 2026

$44.2M

Net Income

Q2 2026

$-6.6M

Free Cash Flow

Q2 2026

$-3.7M

ROIC

Q2 2026

-22.5%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-2.5% YoY

$192.2MFY 2025

FY22 $165.0MFY23 $185.4MFY24 $197.2MFY25 $192.2M

Net Income

+756.7% YoY

$27.0MFY 2025

FY22 $-969.0KFY23 $3.3MFY24 $3.2MFY25 $27.0M

Operating Income

+12.5% YoY

$35.6MFY 2025

FY22 $-60.7MFY23 $28.7MFY24 $31.6MFY25 $35.6M

EPS (Diluted)

+722.2% YoY

$0.74FY 2025

FY22 $-0.12FY23 $0.13FY24 $0.09FY25 $0.74

Total Assets

-12.1% YoY

$107.6MFY 2025

FY22 $111.6MFY23 $155.3MFY24 $122.4MFY25 $107.6M

Total Debt

-5.4% YoY

$109.4MFY 2025

FY22 $128.1MFY23 $121.9MFY24 $115.6MFY25 $109.4M

Op. Cash Flow

-22.2% YoY

$35.2MFY 2025

FY22 $-9.2MFY23 $26.9MFY24 $45.2MFY25 $35.2M

Free Cash Flow

-22.2% YoY

$30.2MFY 2025

FY22 $-9.5MFY23 $26.5MFY24 $38.8MFY25 $30.2M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$192.2M -2.5%	$197.2M +6.4%	$185.4M +12.4%	$165.0M +18.3%	$139.4M	—
Net Income	$27.0M +756.7%	$3.2M -4.8%	$3.3M +442.2%	$-969.0K -108.7%	$11.1M	—
Operating Income	$35.6M +12.5%	$31.6M +10.3%	$28.7M +147.2%	$-60.7M -275.7%	$34.6M	—
EPS (Diluted)	$0.74 +722.2%	$0.09 -30.8%	$0.13 +208.3%	$-0.12	—	—
Total Assets	$107.6M -12.1%	$122.4M -21.2%	$155.3M +39.1%	$111.6M +105.5%	$54.3M +36733.9%	$147.5K
Total Debt	$109.4M -5.4%	$115.6M -5.1%	$121.9M -4.9%	$128.1M +246.6%	$37.0M	—
Operating Cash Flow	$35.2M -22.2%	$45.2M +68.3%	$26.9M +393.6%	$-9.2M -127.2%	$33.7M	—
Free Cash Flow	$30.2M -22.2%	$38.8M +46.3%	$26.5M +379.5%	$-9.5M -129.4%	$32.3M	—

Get alerted when BTMD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for biote Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BTMD

325 CAPITAL LLC
$8.6M4,548,127 sh
Bandera Partners LLC
$3.9M2,065,482 sh
VANGUARD CAPITAL MANAGEMENT LLC
$2.1M1,102,753 sh
ACADIAN ASSET MANAGEMENT LLC
$1.2M625,390 sh
MILLENNIUM MANAGEMENT LLC
$824.2K436,088 sh
DIMENSIONAL FUND ADVISORS LP
$816.1K431,962 sh
BlackRock, Inc.
$691.6K365,945 sh
CITADEL ADVISORS LLC
$569.5K301,310 sh
RICE HALL JAMES & ASSOCIATES, LLC
$496.8K262,842 sh
GEODE CAPITAL MANAGEMENT, LLC
$492.6K260,488 sh

Fund	Value	Shares
325 CAPITAL LLC	$8.6M	4,548,127
Bandera Partners LLC	$3.9M	2,065,482
VANGUARD CAPITAL MANAGEMENT LLC	$2.1M	1,102,753
ACADIAN ASSET MANAGEMENT LLC	$1.2M	625,390
MILLENNIUM MANAGEMENT LLC	$824.2K	436,088
DIMENSIONAL FUND ADVISORS LP	$816.1K	431,962
BlackRock, Inc.	$691.6K	365,945
CITADEL ADVISORS LLC	$569.5K	301,310
RICE HALL JAMES & ASSOCIATES, LLC	$496.8K	262,842
GEODE CAPITAL MANAGEMENT, LLC	$492.6K	260,488

Companies Similar to BTMD

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ASRT

Assertio Holdings, Inc.

AI score

Similar quality profile · 1 shared holders

PERRITT CAPITAL MANAGEMENT INC

III

Information Services Group Inc.

AI score

Similar quality profile · 6 shared holders

PERRITT CAPITAL MANAGEMENT INC JACOBS LEVY EQUITY MANAGEMENT, INC GDS Wealth Management

NATR

NATURES SUNSHINE PRODUCTS INC

AI score

Similar quality profile · 2 shared holders

PERRITT CAPITAL MANAGEMENT INC JACOBS LEVY EQUITY MANAGEMENT, INC

LFVN

Lifevantage Corp

AI score

Similar quality profile

TACT

TRANSACT TECHNOLOGIES INC

AI score

Shared smart-money ownership · 1 shared holders

325 CAPITAL LLC

LFCR

LIFECORE BIOMEDICAL, INC. DE

AI score

Similar quality profile · 1 shared holders

325 CAPITAL LLC

PBYI

PUMA BIOTECHNOLOGY, INC.

AI score

Similar quality profile · 2 shared holders

Abel Hall, LLC Williams & Novak, LLC

AENT

ALLIANCE ENTERTAINMENT HOLDING CORP

AI score

Similar quality profile · 1 shared holders

PERRITT CAPITAL MANAGEMENT INC

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BTMD on your watchlist

Track score changes the day biote Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BTMD a good stock to buy?

13F Pro's AI-powered analysis of biote Corp. (BTMD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BTMD are available on the BTMD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. BTMD is classified as a small company.

Which hedge funds own BTMD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BTMD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of biote Corp.'s investment landscape.